Literature DB >> 22350693

The potential utility of (123)I-mIBG in atrial fibrillation and in the electrophysiology laboratory.

Marc Ovadia1, Kristin S Duque.   

Abstract

A novel indication for (123)I-mIBG has recently been proposed to risk stratify patients with atrial fibrillation. This review puts into perspective the utility and importance of such a risk stratification modality, in the setting of the epidemic of atrial fibrillation, which also relates to the prevalence of heart failure, obesity, hypertension, and stroke. The authors argue that the epic cost of care for patients with paroxysmal and more advanced forms of atrial fibrillation-including catheter ablation, heart failure, and stroke management-coupled with the poor efficacy of all treatment modalities in advanced atrial fibrillation, make necessary a paradigm shift where only paroxysmal atrial fibrillation that demonstrably will turn into permanent fibrillation should be targeted aggressively. If this premise is accepted, then (123)I-mIBG nuclear imaging for risk stratification becomes a vital tool for the care of the individual patient, as well as for disease control and cost containment in the population, since (123)I-mIBG scanning alone can predict (with hazard ratios of the order of 3.0-5.0) the future occurrence of permanent atrial fibrillation or heart failure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350693     DOI: 10.1007/s11886-012-0249-y

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  20 in total

Review 1.  Development of mIBG as a cardiac innervation imaging agent.

Authors:  David M Raffel; Donald M Wieland
Journal:  JACC Cardiovasc Imaging       Date:  2010-01

2.  Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study).

Authors:  Giuseppe Stabile; Emanuele Bertaglia; Gaetano Senatore; Antonio De Simone; Franco Zoppo; Giovanni Donnici; Pietro Turco; Pietro Pascotto; Massimo Fazzari; Dino Franco Vitale
Journal:  Eur Heart J       Date:  2005-10-07       Impact factor: 29.983

3.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial.

Authors:  Oussama M Wazni; Nassir F Marrouche; David O Martin; Atul Verma; Mandeep Bhargava; Walid Saliba; Dianna Bash; Robert Schweikert; Johannes Brachmann; Jens Gunther; Klaus Gutleben; Ennio Pisano; Dominico Potenza; Raffaele Fanelli; Antonio Raviele; Sakis Themistoclakis; Antonio Rossillo; Aldo Bonso; Andrea Natale
Journal:  JAMA       Date:  2005-06-01       Impact factor: 56.272

4.  Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation.

Authors:  Hakan Oral; Bradley P Knight; Hiroshi Tada; Mehmet Ozaydin; Aman Chugh; Sohail Hassan; Christoph Scharf; Steve W K Lai; Radmira Greenstein; Frank Pelosi; S Adam Strickberger; Fred Morady
Journal:  Circulation       Date:  2002-03-05       Impact factor: 29.690

5.  Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop.

Authors:  Emelia J Benjamin; Peng-Sheng Chen; Diane E Bild; Alice M Mascette; Christine M Albert; Alvaro Alonso; Hugh Calkins; Stuart J Connolly; Anne B Curtis; Dawood Darbar; Patrick T Ellinor; Alan S Go; Nora F Goldschlager; Susan R Heckbert; José Jalife; Charles R Kerr; Daniel Levy; Donald M Lloyd-Jones; Barry M Massie; Stanley Nattel; Jeffrey E Olgin; Douglas L Packer; Sunny S Po; Teresa S M Tsang; David R Van Wagoner; Albert L Waldo; D George Wyse
Journal:  Circulation       Date:  2009-02-03       Impact factor: 29.690

6.  Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man.

Authors:  J C Sisson; B Shapiro; L Meyers; S Mallette; T J Mangner; D M Wieland; J V Glowniak; P Sherman; W H Beierwaltes
Journal:  J Nucl Med       Date:  1987-10       Impact factor: 10.057

7.  Atrial fibrillation: Preventing serious complications during AF ablation.

Authors:  Aman Chugh; Hakan Oral
Journal:  Nat Rev Cardiol       Date:  2009-09       Impact factor: 32.419

8.  Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study.

Authors:  Takeshi Kato; Takeshi Yamashita; Kouichi Sagara; Hiroyuki Iinuma; Long-Tai Fu
Journal:  Circ J       Date:  2004-06       Impact factor: 2.993

9.  Trans-septal catheterization in the electrophysiology laboratory: data from a multicenter survey spanning 12 years.

Authors:  Roberto De Ponti; Riccardo Cappato; Antonio Curnis; Paolo Della Bella; Luigi Padeletti; Antonio Raviele; Massimo Santini; Jorge A Salerno-Uriarte
Journal:  J Am Coll Cardiol       Date:  2006-02-09       Impact factor: 24.094

10.  Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial.

Authors:  David J Wilber; Carlo Pappone; Petr Neuzil; Angelo De Paola; Frank Marchlinski; Andrea Natale; Laurent Macle; Emile G Daoud; Hugh Calkins; Burr Hall; Vivek Reddy; Giuseppe Augello; Matthew R Reynolds; Chandan Vinekar; Christine Y Liu; Scott M Berry; Donald A Berry
Journal:  JAMA       Date:  2010-01-27       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.